Replies to post #100746 on Biotech Values

[DewDiligence]

The data from the table in #msg-52978824 could probably provide sufficient ammunition to propel a Telaprevir vs Boceprevir debate from now until the AASLD meeting in Oct-Nov, if we were so inclined.